Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Filip Y F L de Vos Winand N M Dinjens Annemiek M E Walenkamp Martin J van den Bent Martin Taphoorn |
| Publication date | July 15, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |